Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: Prolactin involvement in human breast cancer and significance for toxicology risk assessments

Journal of Applied Toxicology

Volumn 25, Issue 3, 2005, Pages 179-183

  Harvey, Philip W ^a  

^a UK   (United Kingdom)

Author keywords

Breast cancer; Carcinogenesis; Dopamine agonist; Dopamine antagonist; Human; Mammary; Mouse; Prolactin; Rat; Tumour

Indexed keywords

ANTIEMETIC AGENT; BRCA1 PROTEIN; CABERGOLINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; MITOGENIC AGENT; NEUROLEPTIC AGENT; PROLACTIN;

APOPTOSIS; ARTICLE; AUTOCRINE EFFECT; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CANCER RISK; COLON CANCER; DRUG EFFECT; DRUG MECHANISM; GENOTOXICITY; HUMAN; HYPERPROLACTINEMIA; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROGNOSIS; PROLACTIN RELEASE; PROLACTIN SYNTHESIS; RISK ASSESSMENT; UPREGULATION;

ANIMALS; BREAST NEOPLASMS; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MIDDLE AGED; POSTMENOPAUSE; PROLACTIN; RATS; RISK ASSESSMENT;

RODENTIA;

EID: 20444406891     PISSN: 0260437X     EISSN: None     Source Type: Journal    
DOI: 10.1002/jat.1063     Document Type: Article

References (41)

1. Asa SL. 2001. Transgenic and knockout mouse models clarify pituitary development, function and disease. Brain Pathol. 11: 370-383.
2. Baldrick P. 2005. Carcinogenicity evaluation: comparison of tumor data from dual control groups in Sprague-Dawley rat. Toxicol. Pathol. 33: 283-291.
3. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Ghosh N, Chikhlikar PR, Trivedi TI. 2000. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience. Eur. J. Surg. Oncol. 26: 540-547.
4. Bogdanffy MS, O'Connor JC, Hansen JF, Gaddamidi V, Van Pelt CS, Green JW, Cook JC. 2000. Chronic toxicity and oncogenicity bioassay in rats with the chloro triazine herbicide cyanazine. J. Toxicol. Environ. Health A 60: 567-586.
5. Bonneterre J, Mauriac L, Weber B, Roche H, Fargeot P, Tubiana-Hulin M, Sevin M, Chollet P, Cappelaere P. 1988. Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial. Eur. J. Cancer Clin. Oncol. 24: 1851-1853.
6. Cargill SL, Medrano JF, Anderson GB. 1999. Infertility in a line of mice with the high growth mutation is due to luteal insufficiency resulting from disruption at the hypothalamic-pituitary axis. Biol. Reprod. 61: 282-287.
7. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. 2003. The role of prolactin in mammary carcinoma. Endocr. Rev. 24: 1-27.
8. Cohen SM, Klaunig J, Meek E, Hill RN, Pastoor T, Lehman-McKeeman L, Bucher J, Longfellow DG, Seed J, Dellarco V, Fenner-Crisp P, Patton D. 2004. Evaluating the human relevance of chemically induced animal tumors. Toxicol. Sci. 78: 181-186.
9. Das R, Vonherhaar BK. 1997. Prolactin as a mitogen in mammary cells. J. Mammary Gland Biol. Neoplasia 2: 29-39.
10. Favy DA, Rio R, Maurizis JC, Hizel C, Bignon YJ, Bernard-Gallon D. 1999. Prolactin dependent up-regulation of BRCA1 expression in human breast cancer cell lines. Biochem. Biophys. Res Commun. 258: 284-291.
11. Fritze D, Queisser W, Schmid H, Kaufmann M, Massner B, Westerhausen M, Schmidt R, Edler L, Abel U. 1986. Prospective randomized trial concerning hyper- and normoprolactinemia and the use of bromoergocriptine in patients with metastatic breast cancer. Onkologie 9: 305-312.
12. Gill S, Peston D, Vonderhaar BK, Shousa S. 2001. Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study. J. Clin. Pathol. 54: 956-960.
13. Gold LS, Stone TH, Manley NB, Bernstein L. 1991. Target organs in chronic bioassays of 533 chemical carcinogens. Environ. Health Perspect. 93: 233-246.
14. Goffin V, Touraine P, Pichard C, Bernichtein S, Kelly P. 1999. Should prolactin be reconsidered as a therapeutic target in human breast cancer? Mol. Cell Endocrinol. 151: 79-87.
15. Goffin V, Binart N, Touraine P, Kelly PA. 2002. Prolactin: the new biology of an old hormone. Annu. Rev. Physiol. 64: 47-67.
16. Gopinath C. 1995. The predictive value of pathological findings in animal toxicity studies. J. Toxicol. Pathol. 8: 89-100.
17. Gopinath C. 1999. Comparative endocrine carcinogenesis. In Endocrine and Hormonal Toxicology, Harvey PW, Rush KC, Cockbum A (eds). John Wiley: Chichester.
18. Greaves P. 1999. Histopathology of Preclinical Toxicity Studies: Interpretation and Relevance in Drug Safety Evaluation. Elsevier Science: Amsterdam.
19. Gutzman JH, Rugowski DE, Schroeder MD, Watters JJ, Schuler LA. 2004. Multiple kinase cascades mediate prolactin signals to activate protein-1 in breast cancer cells. Mol. Endocrinol. 18: 3064-3075.
20. Haddad PM, Wieck A. 2004. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64: 2291-2314.
21. Hankinson SE, Willett WC, Michaud DS, Manson JE, Colditz GA, Longcope C, Rosner B, Speizer FE. 1999. Plasma prolactin levels and subsequent risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 91: 629-634.
22. Holtkamp W, Nagel GA. 1988. Bromocriptine in chemotherapy-resistant, metastatic breast cancer. Results of the GO-MC-BROMO 2/82 AIO study. Onkologie 11: 121-127.
23. Holtkamp W, Nagel GA, Wander HE, Rauschecker HF, von Heyden D. 1984. Hyperprolactinaemia is an indicator of progressive disease and poor prognosis in advanced breast cancer. Int. J. Cancer 34: 323-328.
24. Kleinberg DL. 1987. Prolactin and breast cancer. N. Engl. J. Med. 316: 269-271.
25. Lissoni P, Vaghi M, Villa S, Bodraska A, Cerizza L, Tancini G, Gardani GS. 2003. Antiprolactinaemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with an LHRH analogue, tamoxifen and the long acting antiprolactin drug carbergoline. Anticancer Res. 23 (1B): 733-736.
26. Meng J, Tsai-Morris CH, Dufau ML. 2004. Human prolactin receptor variants in breast cancer: low ratio of short forms to the long form human prolactin receptor associated with mammary carcinoma. Cancer Res. 64: 5677-5682.
27. Mershon J, Sall W, Mitchner N, Ben-Jonathan N. 1995. Prolactin is a local growth factor in rat mammary tumors. Endocrinology 136: 3619-3623.
28. Mujagic Z, Mujagic H. 2004. Importance of serum prolactin determination in metastatic breast cancer patients. Croat. Med. J. 45: 176-180.
29. Neumann F. 1991. Early indicators for carcinogenesis in sex-hormone-sensitive organs. Mutat. Res. 248: 341-356.
30. O'Connor JC, Plowchalk DR, Van Pelt CS, Davis LG, Cook JC. 2000. Role of prolactin in chloro-s-triazine rat mammary tumorigenesis. Drug Chem. Toxicol. 23: 575-601.
31. Perks CM, Keith AJ, Goodhew KL, Savage PB, Winters ZE, Holly JM. 2004. Prolactin acts as a potent survival factor for human breast cancer cell lines. Br. J. Cancer 91: 305-311.
32. Schroeder MD, Symowicz J, Schuler LA. 2002. PRL modulates cell cycle regulators in mammary tumour epithelial cells. Mol. Endocrinol. 16: 45-57.
33. Stevens JT, Breckenridge CB, Wetzel L. 1999. A risk characterization for atrazine: oncogenicity profile. J. Toxicol. Environ. Health A 56: 69-109.
34. Thordarson G, Galosy S, Gudmundsson GO, Newcomer B, Sridara R, Talamantes F. 1997. Interaction of mouse placental lactogens and androgens in regulating progesterone release in cultured mouse luteal cells. Endocrinology 138: 3236-3241.
35. Tworoger SS, Eliassen AH, Rosner B, Sluss P, Hankinson SE. 2004. Plasma prolactin concentrations and risk of postmenopausal breast cancer. Cancer Res. 64: 6814-6819.
36. Vonderhaar BK. 1989. Estrogens are not required for prolactin induced growth of MCF-7 human breast cancer cells. Cancer Lett. 47: 105-110.
37. Vonderhaar BK. 1998. Prolactin: the forgotten hormone in breast cancer. Pharmacol. Ther. 79: 169-178.
38. Vonderhaar BK. 1999. Prolactin involvement in breast cancer. Endocr. Relat. Cancer 6: 389-404.
39. Wakefield LM, Thordarson G, Nieto AI, Shymala G, Galvez JJ, Anver MR, Cardiff RD. 2003. Spontaneous pituitary abnormalities and mammary hyperplasia in FVB/NCr mice: implications for mouse modelling. Comp. Med. 53: 424-432.
40. Wang DY, Hampson S, Kwa HG, Moore JW, Bulbrook RD, Fentiman IS, Hayward JL, King RJ, Millis RR, Rubens RD. 1986. Serum prolactin levels in women with breast cancer and their relationship to survival. Eur. J. Cancer Clin. Oncol. 22: 487-492.
41. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levi R, Avorn J. 2002. Dopamine antagonists and the development of breast cancer. Arch. Gen. Psychiatry 59: 1147-1154.